Meeting
2023 ASCO Annual Meeting
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.
Authors
Michael Masetti
Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, München, Germany
Michael Masetti , Salah-Eddin Al-Batran , Thorsten Oliver Goetze , Peter C. Thuss-Patience , Jorge Riera-Knorrenschild , Eray Goekkurt , Gunnar Folprecht , Thomas Jens Ettrich , Udo Lindig , Kim Barbara Luley , Daniel Pink , Tobias Nicolaas Dechow , Disorn Sookthai , Sabine Junge , Claudia Pauligk , Sylvie Lorenzen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03647969
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4043)
DOI
10.1200/JCO.2023.41.16_suppl.4043
Abstract #
4043
Poster Bd #
364
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
First Author: Salah-Eddin Al-Batran
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
First Author: Sylvie Lorenzen
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla